Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.71
- Piotroski Score 4.00
- Grade Outperform
- Symbol (GH)
- Company Guardant Health, Inc.
- Price $30.98
- Changes Percentage (0.98%)
- Change $0.3
- Day Low $30.30
- Day High $31.16
- Year High $37.04
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $40.00
- High Stock Price Target $125.00
- Low Stock Price Target $36.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.92
- Trailing P/E Ratio -7.31
- Forward P/E Ratio -7.31
- P/E Growth -7.31
- Net Income $-479,449,000
Income Statement
Quarterly
Annual
Latest News of GH
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Bitcoin at record highs, sets sights on $100,000
LONDON (Reuters) - Bitcoin touched a fresh record high on Friday, with its sights set firmly on the $100,000 barrier, in a stellar rally for the cryptocurrency sparked by expectations of a more fr...
By Reuters | 2 hours ago -
Analysis-Record 2025 bond sales risk higher euro zone borrowing costs
By Harry RobertsonLONDON (Reuters) - Investors will have to buy a record amount of euro zone government bonds for a third straight year in 2025 and without the ECB in the market, potentially addi...
By Reuters | 4 hours ago -
Adani's Australian coal unit faces human rights complaint
By Melanie BurtonMELBOURNE (Reuters) - India's Adani Group, whose billionaire chairman has been indicted for fraud by U.S. prosecutors, is facing accusations of racism at its Australian coal unit ...
By Reuters | 4 hours ago
